Navigation Links
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Date:3/13/2008

or the

cohort dosed least frequently.

-- As expected in this short term study, the levels of relevant markers

of Gaucher disease including platelet counts, hemoglobin levels,

glucocerebroside (substrate) levels, chitotriosidase activity and

pulmonary activation-related chemokine (PARC) levels were maintained.

"These data give us great confidence in moving our Gaucher program forward," said John F. Crowley, President and CEO of Amicus Therapeutics. "In addition to a 6-month Phase 2 study in individuals naive to ERT, which is currently underway, we plan to initiate a longer-term study in individuals switching from enzyme replacement therapy to Plicera in the second half of this year."

As of November 2007, Plicera is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.

About Gaucher Disease

Gaucher disease is a lysosomal storage disorder caused by inherited genetic mutations in the GBA gene, which result in deficient activity of the enzyme acid beta-glucosidase, also known as glucocerebrosidase (GCase). Deficient GCase activity leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets and skeletal complications. In some cases there is significant impairment of the central nervous system.

Gaucher disease is estimated to affect approximately 10,000 people in the developed world. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in Plicera in the United States and the European Commission has designated Plicera as an orphan medicinal product in the European Union.

About Amicus Therapeutics

Amicus Therapeutics is a biopharm
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Follow us on ... revolutionize the world has attracted diverse players including ... start-ups. The early years of nanotechnology development was ... to the high risks involved, which deterred private ... this evolving technology have been growing over the ...
(Date:9/19/2014)... Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... difficult to manufacture proteins including biosimilar therapeutics, today announced ... Annual NewsMakers in the Biotech Industry conference in ... , chief executive officer of Pfenex, will provide an ... on Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the ... Pre-packed Chromatography Columns"  report to their offering.  ... columns market is one of the fastest-growing segments ... at $1.2 billion in 2013, and expected to ...
(Date:9/18/2014)... September 18, 2014 HealthTronics, ... and interventional radiology products and services, announced that ... cryotherapy and cryoablation) versus external beam radiotherapy (EBRT) ... the American Urological Association (MAAUA) Annual Meeting in ... Relative Effectiveness of Cryosurgery and External Beam Radiation ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... (NYSE AMEX: IBIO ) today announced that it has ... Annual Stockholders Meeting to be held December 8, 2011 at iBio,s ... AM ET. Although only stockholders of record as ... entitled to vote at the meeting, anyone with proof of ownership ...
... materials science and engineering (MSE) researchers have demonstrated ... how energy levels align in a critical group ... breakthrough in the development of sustainable technologies such ... (OLEDs). Transition metal oxides, which are best-known ...
... Nov. 5, 2011 Jennerex, Inc., a private clinical-stage ... of first-in-class targeted oncolytic products for cancer, today presented ... trial of JX-594 in patients with advanced liver cancer ... the high JX-594 dose group versus the low dose ...
Cached Biology Technology:iBio Sets Record Date and Location for December 8 Annual Meeting of Stockholders 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 3Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 4Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 5Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 6
(Date:9/18/2014)... stored in DNA, tiny strands of nucleic acid that ... express this genetic data, our DNA is copied into ... that perform tasks in our cells. , Several ... molecule. Unlike all other known RNAs, this molecule is ... are abundant, little has been known about how they ...
(Date:9/18/2014)... Arizona turned its newborn screening program into a model other ... it the first-ever Newborn Screening Quality Award from the March ... Humble, M.P.H., Arizona,s Department of Health Services director, with the ... a policy of full transparency for the length of time ... the lab for analysis, and set a target of having ...
(Date:9/18/2014)... happy-go-lucky characters, so you might expect that most would ... fact some dogs are distinctly more pessimistic than others, ... "This research is exciting because it measures positive and ... offers researchers and dog owners an insight into the ... Melissa Starling, from the Faculty of Veterinary Science. Her ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... Health, science and medical reporters are invited to register ... Scientific Meeting March 24 at Moscone Center (North), San ... to focus on the results of care-changing investigations that ... options, advance patient care and improve quality of life. ...
... Seeking to maximise the value of computational modelling ... Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), ... (PETA) Foundation has produced a free resource for ... on the use of Quantitative Structure Activity Relationships ...
... 2007, a controversial pesticide was approved by the Food and ... in California and Florida. Farm workers and scientists protested the ... is a known carcinogen. Now, MU researchers are studying the ... could be made more efficient and safer for those living ...
Cached Biology News:Media alert: Press registration open for 2012 SIR Annual Scientific Meeting 2PETA launches in silico testing resource to reduce number of animal tests 2MU scientists study how to improve pesticide efficiency 2
... Cell permeable fluorescent minor groove-binding probe ... of double-stranded DNA (preferentially to AT rich ... approximately 20 times greater than DAPI alone. ... ethidium bromide for staining DNA in agarose ...
... The 96 PW is an intelligent full ... washing all wells simultaneously. This instrument gives you ... and outstanding washing efficiency , Performance ... throughput and excellent wash efficiency. A dispense precision ...
... CE 4100 high pressure dual piston pump and ... for added flexibility. The system is ... unit, CE 4901., The CE 4901 PowerStream software ... with Windows 98 and 2000, offers the same ...
...
Biology Products: